Is NAD+ a Peptide? No. Here's What It Actually Is (2026)

Key Takeaways

• NAD+ (nicotinamide adenine dinucleotide) is a dinucleotide coenzyme. It contains no amino acids and no peptide bonds. Calling it a "peptide" is chemically incorrect.
• "NAD peptide" is a marketing term that emerged because wellness clinics sell NAD+ injections alongside actual peptides (BPC-157, MOTS-c, Epithalon). Proximity on a shelf does not change molecular structure.
• Real peptides that interact with NAD+ biology exist. MOTS-c, a 16-amino-acid mitochondrial peptide, activates AMPK and influences energy metabolism. But MOTS-c is MOTS-c, and NAD+ is NAD+. They are not the same molecule.
• For most people interested in raising NAD+ levels, oral precursors like NMN and NR are the evidence-backed starting point, not injectable "NAD peptide" protocols that typically cost $400 to $1,500 per session.

Why Do People Call NAD+ a Peptide?

Three things happened at roughly the same time, and their overlap created the confusion.

Injectable NAD+ entered the wellness clinic market in the early 2020s. Clinics that already offered peptide injections (BPC-157, Thymosin Beta-4, GHK-Cu) added NAD+ IV drips and subcutaneous NAD+ shots to their service menu. Patients started receiving NAD+ in the same appointment, from the same nurse, through the same syringe type, alongside their peptide protocols. The delivery method looked identical, so the assumption followed: NAD+ must be a peptide too.

Compounding pharmacies made it worse. Their product catalogs listed NAD+ right next to MOTS-c and Epithalon. Online peptide vendors did the same. When you search for "peptides" on these sites, NAD+ shows up in the results. That product placement reinforced the misclassification.

Then the marketing language solidified. "NAD+ peptide therapy" sounds more specific and scientific than "NAD+ injection." Clinics discovered that framing NAD+ as a peptide made it easier to sell within existing peptide packages. The label stuck, even though it describes nothing about the molecule's actual chemistry.

None of these reasons have anything to do with biochemistry. NAD+ did not become a peptide. It got placed next to peptides, and the commercial language blurred the distinction.

What Makes Something a Peptide?

A peptide is a short chain of amino acids connected by a specific type of chemical bond called a peptide bond. That bond forms when the carboxyl group of one amino acid reacts with the amino group of the next, releasing a molecule of water. Chains shorter than about 50 amino acids are typically called peptides; longer chains are called proteins.

Some examples of real peptides used in the longevity and wellness space:

MOTS-c is probably the one most people have heard of. Sixteen amino acids, encoded not in your nuclear DNA but in your mitochondrial DNA. It activates AMPK, the enzyme your cells use to sense whether energy is running low. In July 2026, an FDA advisory committee voted 7-5 to recommend adding MOTS-c to the Section 503A compounding list. Final rulemaking is still pending, and no completed human efficacy trial for native MOTS-c exists.

BPC-157 is a 15-amino-acid peptide pulled from a protein in human gastric juice, studied mostly for wound healing and tissue repair. Also reviewed by the FDA advisory committee in July 2026.

Epithalon is only four amino acids long, synthetic, and studied for its potential effect on telomerase activation.

Each of these is built from amino acids linked by peptide bonds. That is what makes them peptides. NAD+ has none of these features.

What Is NAD+ Actually Made Of?

NAD+ is a dinucleotide. The name tells you the structure: two nucleotides joined through their phosphate groups. One nucleotide carries an adenine base (the same "A" base in your DNA). The other carries a nicotinamide group, which is a form of vitamin B3.

Its chemical formula is C₂₁H₂₇N₇O₁₄P₂. Molecular weight: approximately 663 daltons. That formula contains zero amino acids. The bonds holding NAD+ together are phosphodiester bonds, not peptide bonds. Phosphodiester bonds connect nucleotides; peptide bonds connect amino acids. These are different chemical reactions producing different molecular architectures.

In structural terms, NAD+ is closer to a fragment of DNA or RNA than to any peptide. If you had to place it in a family, it belongs with the nucleotide coenzymes (FAD, NADP+, coenzyme A), not with the peptide signaling molecules.

A quick way to settle it: look at the name. Nicotinamide adenine dinucleotide. The word "dinucleotide" tells you the classification right there. Two nucleotides. Not "dipeptide," which would mean two amino acids. The naming convention in biochemistry is precise on this point, even if the marketing is not.

Your body makes NAD+ through several biosynthesis pathways, all starting from vitamin B3 derivatives or the amino acid tryptophan. The salvage pathway, which recycles nicotinamide back into NAD+ through the intermediate NMN, accounts for most daily NAD+ production. The enzyme NAMPT is the bottleneck in this recycling loop, and its expression declines with age. That decline is one reason NAD+ levels drop as you get older, and it is why researchers study NMN and NR supplementation: both of these precursors enter the pathway past the NAMPT bottleneck. For the full biosynthesis explanation and the latest 2026 research on NAD+ decline, see What Is NAD+? Benefits, Function & Why It Declines With Age.

What About "NAD+ Peptide" Skincare Products?

A separate branch of the "NAD peptide" conversation involves topical skincare products. Brands like Eqqualberry market NAD+ peptide boosting serums, creams, and toners. These are cosmetic products, not injectable "NAD peptide therapy," and they sit in an entirely different regulatory and scientific context.

The premise is that topical NAD+ (or its precursors NMN/NR) can penetrate the skin barrier, reach living cells in the dermis, and support local NAD+ levels involved in skin cell repair and turnover. A 2024 study in Cells (Kang et al.) explored combining exogenous NAD+ with CD38 inhibitors to preserve NAD+ levels in skin cells, finding that the combination improved cellular NAD+ availability in lab settings. Whether that translates to visible anti-aging effects from a retail cream remains unproven in published clinical trials.

The "peptide" in these product names is often even more confusing than in the injection context. Some of these formulations do contain actual peptide ingredients alongside NAD+ (copper peptides, for example, are common in anti-aging serums). So the product may genuinely contain both NAD+ and peptides. But calling the entire product an "NAD peptide serum" still conflates the two different types of ingredients into one name, reinforcing the misconception that NAD+ itself is a peptide.

If you are considering a topical NAD+ skincare product, the key question is not whether it "is" a peptide but whether topical NAD+ delivery has evidence behind it. As of September 2026, the evidence is preclinical. No published human clinical trial has demonstrated that topically applied NAD+ or NMN produces measurable improvements in skin aging markers compared to placebo.

NAD+ vs Peptides: How They Work Differently

The functional difference is as stark as the structural one.

NAD+ is a workhorse, not a messenger. It picks up electrons during the breakdown of food and delivers them to the mitochondrial electron transport chain, generating ATP (cellular energy). It also serves as a substrate that gets consumed by sirtuins (gene regulators), PARPs (DNA repair enzymes), and CD38 (an immune-related NADase). These are stoichiometric reactions: each time a sirtuin activates, one molecule of NAD+ is destroyed and must be replaced. Your body cycles through its entire NAD+ pool multiple times per day.

Peptides do the opposite. They carry messages. They bind to specific receptors on cell surfaces or inside cells and trigger a downstream biological response. MOTS-c binds to AMPK pathways. BPC-157 interacts with growth factor and nitric oxide systems. GHK-Cu modulates gene expression related to collagen and wound repair. These are catalytic or receptor-mediated interactions, not stoichiometric consumption. A peptide delivers a signal; NAD+ gets burned as fuel.

When a clinic offers "NAD+ peptide therapy," what they are actually doing in most cases is administering NAD+ (a coenzyme) through IV or injection, sometimes alongside one or more actual peptides. The "peptide" in the name describes the treatment bundle, not the NAD+ molecule itself.

What About "NAD+ Peptide Injections"?

When someone searches for "NAD peptide injection" or "NAD 500mg peptide," they are almost always looking for injectable NAD+ sold through a compounding pharmacy or wellness clinic. The product itself is pharmaceutical-grade NAD+ dissolved in sterile saline. It contains no peptides.

These injections are administered subcutaneously (into the fat layer under the skin, typically the abdomen or thigh) or intravenously (as a slow drip over 1 to 4 hours). IV sessions at US wellness clinics typically cost $400 to $1,500 per session. Subcutaneous NAD+ injections run lower, usually $200 to $500 per month through telehealth providers.

As of September 2026, injectable NAD+ is not an FDA-approved drug. It is prepared by compounding pharmacies under physician prescription. The 2026 PRISMA systematic review (Gallagher & Emmanuel, Ageing Research Reviews) found zero eligible outcomes trials evaluating intravenous or intramuscular NAD+ for anti-aging or wellness indications. The biochemical logic is sound (inject NAD+ directly into the bloodstream to bypass digestion), but the clinical evidence base for this delivery route is essentially nonexistent in controlled settings.

By contrast, oral NAD+ precursors like NMN and NR have been tested in over 30 human trials. Both approximately double circulating NAD+ within 14 days (Christen et al., 2026, Nature Metabolism), at a fraction of the cost. We break down IV vs injection vs oral in NAD+ Injections and NAD+ IV Therapy if you want the delivery method comparison.

Is There a Real Connection Between NAD+ and Peptides?

Yes, but it runs through biology, not through product labels.

Several genuine peptides interact with NAD+ pathways at the molecular level. This is probably the legitimate root of why people associate the two concepts.

MOTS-c is the one worth knowing about. This 16-amino-acid mitochondrial peptide activates AMPK, the same energy-sensing enzyme that gets upregulated when NAD+ levels are high and sirtuin activity increases. MOTS-c levels decline with age in both rodents and humans. In mouse models, MOTS-c injections improved insulin sensitivity, exercise capacity, and metabolic markers. An FDA advisory committee voted 7-5 in July 2026 to recommend MOTS-c for the compounding list, though no human efficacy trial for the native peptide has been completed. MOTS-c works alongside NAD+ in the broader mitochondrial maintenance system, but it is a separate molecule with separate chemistry and separate regulatory status.

Humanin is a second mitochondrial-derived peptide (24 amino acids) that appears to interact with cellular stress responses linked to NAD+ metabolism. Research here is earlier-stage than MOTS-c.

The takeaway: NAD+ and certain peptides participate in overlapping biological pathways (mitochondrial function, energy sensing, aging). That shared biology does not make NAD+ a peptide any more than gasoline becomes a tire because both are found in a car.

NAD+ vs Peptide Hormones: A Common Mix-Up

One specific source of confusion deserves its own note, because it comes up constantly in the longevity and weight-loss space. Some of the most talked-about "peptides" right now are peptide hormones, and people sometimes lump NAD+ in with them because they all get discussed in the same metabolic-health conversations.

Semaglutide and tirzepatide, the drugs behind Ozempic, Wegovy, Mounjaro, and Zepbound, are peptides. Specifically, they are GLP-1 receptor agonists: engineered peptide molecules that mimic a natural gut hormone to regulate blood sugar and appetite. They are made of amino acids, they act on specific receptors, and they are FDA-approved drugs with extensive trial data. They are peptides in the full, correct sense of the word.

NAD+ is none of that. It is a coenzyme, not a hormone. It does not act on a receptor the way GLP-1 agonists do. It is not a drug. The only thing NAD+ shares with these peptide hormones is that both appear in discussions about metabolism and aging. That shared conversational context is not a chemical relationship. Grouping NAD+ with semaglutide because both are "metabolic health compounds" makes about as much sense as grouping aspirin with insulin because both are things you might take for your health.

This distinction matters practically because the two categories carry completely different regulatory status, evidence bases, safety profiles, and delivery requirements. If you are researching metabolic health and see NAD+ and GLP-1 peptides discussed together, keep them mentally separate. One is a coenzyme your body makes; the other is a class of engineered peptide drugs. They are not variations on a theme.

The Regulatory Picture: Why the "Peptide" Label Matters Legally

This is not just a chemistry debate. The peptide vs. coenzyme classification has real regulatory consequences.

In the United States, peptides sold for injection are regulated as drugs or must be compounded under FDA Section 503A by a licensed pharmacy with a physician's prescription. The FDA has been actively tightening oversight of compounded peptides. In July 2026, the Pharmacy Compounding Advisory Committee reviewed seven peptides (including MOTS-c, BPC-157, and Epithalon) for potential inclusion on the 503A Bulks List. These reviews determine whether compounding pharmacies can legally prepare and sell these substances.

NAD+ occupies a gray zone. Injectable NAD+ is not an FDA-approved drug, but it is compounded and prescribed by physicians at wellness clinics across the country. Oral NAD+ precursors (NMN and NR) are sold as dietary supplements under the Dietary Supplement Health and Education Act (DSHEA), though NMN's supplement status has been contested by the FDA, which briefly attempted to classify it as an investigational new drug. As of September 2026, NMN supplements remain widely available in the US retail market.

When a clinic bundles NAD+ with actual peptides under a single "peptide therapy" package, it blurs the regulatory category of each component. A patient receiving "NAD peptide therapy" may not realize that the NAD+ portion and the BPC-157 portion carry different regulatory statuses, different evidence bases, and different risk profiles. The terminology obscures distinctions that a patient needs to make informed decisions.

What Does "NAD Peptide" Do? (What People Are Really Asking)

When someone searches "what does NAD peptide do" or "NAD peptide benefits," they are asking about NAD+ itself. The word "peptide" is just trailing along from the commercial framing. So here is what NAD+ actually does:

It carries electrons from the food you eat to your mitochondria, where those electrons generate ATP. Without NAD+, the electron transport chain stalls. This is not a theoretical benefit. It is a prerequisite for being alive.

It fuels DNA repair. PARP enzymes consume NAD+ to build poly(ADP-ribose) chains that recruit repair proteins to broken DNA. As you age and DNA damage accumulates, PARP activity increases and NAD+ consumption rises.

It regulates gene expression. Sirtuins (SIRT1 through SIRT7) use NAD+ as a substrate to remove acetyl tags from proteins, regulating gene expression, mitochondrial function, and inflammatory signaling. When NAD+ drops, sirtuin activity drops with it.

And it intersects with your immune system. CD38, an enzyme on immune cells, hydrolyzes NAD+ as part of immune responses. CD38 expression rises with age-related inflammation, and this increase is now recognized as the primary driver of age-related NAD+ decline (Camacho-Pereira et al., 2016, Cell Metabolism).

These are real biological functions with strong scientific support. None of them require NAD+ to be a peptide. For the full evidence review, see What Is NAD+? Benefits, Function & Why It Declines With Age.

"NAD Peptide" Dosing: What the Data Actually Shows

"NAD peptide dosage" and "NAD peptide dosing chart" are among the most searched terms in this cluster. People asking this question want to know how much NAD+ to take, regardless of the peptide mislabel.

The answer depends entirely on the delivery method.

With oral precursors (NMN or NR), clinical trial doses range from 250 mg to 1,200 mg per day for NMN, and 300 mg to 1,000 mg per day for NR. The January 2026 head-to-head trial (Christen et al., Nature Metabolism) used 1,000 mg/day of each and found both approximately doubled blood NAD+ at 14 days. No serious adverse events at any studied dose. This is where the evidence base is strongest.

For IV NAD+ infusions, clinic protocols typically use 250 mg to 1,000 mg per session, administered over 1 to 4 hours. There is no standardized dosing protocol because there are no published randomized controlled trials establishing one. Doses are based on clinical experience at individual clinics, not on controlled evidence.

For subcutaneous NAD+ injections, common self-injection doses range from 100 mg to 500 mg, typically daily or every other day. Again, no RCT-based dosing guideline exists. The February 2026 Berven et al. pharmacokinetic study (iScience) measured blood NAD+ kinetics with oral precursors, not injectable NAD+, and found that blood levels plateaued after approximately two weeks.

NAD+ Peptide Side Effects

"NAD peptide side effects" is another high-volume search term. Again, the side effects people are asking about belong to NAD+ or its precursors, not to peptides.

Oral precursors (NMN, NR) have been well-tolerated across 33 human intervention studies reviewed in the 2026 PRISMA systematic review. No serious adverse events were attributed to supplementation. Mild, transient effects reported in some trials include flushing (more common with niacin than NMN or NR), mild GI discomfort, and headache.

IV NAD+ infusions commonly cause chest tightness, nausea, headache, and a sensation of pressure or heat during the drip. These effects are typically dose-rate dependent: slowing the drip rate reduces symptoms. They resolve after the infusion ends.

Subcutaneous NAD+ injections can cause stinging or burning at the injection site. Some users report brief nausea. These reactions are generally self-limiting.

Where do you inject NAD+?

Subcutaneous NAD+ is injected into the fatty tissue of the abdomen or thigh using an insulin syringe, after cleaning the site with an alcohol swab. The injection angle is typically 45 degrees for subcutaneous delivery. Some clinic protocols specify rotating injection sites to reduce local irritation. IV NAD+ is administered through a peripheral vein, usually in the arm, by a trained healthcare provider. Self-injection of subcutaneous NAD+ at home is increasingly common through telehealth programs, where a physician prescribes the compounded NAD+ and the patient self-administers after initial instruction. IV NAD+ should never be self-administered due to the risk of infiltration, infection, and adverse reactions that require medical monitoring.

Important: This describes how injectable NAD+ is administered in clinical settings. It is not a how-to guide. Always consult your doctor before starting any injectable protocol. Dosing, delivery method, and whether NAD+ is appropriate for you at all are medical decisions that require a licensed provider who knows your health history.

NAD+ peptide research: What is being studied?

The term "NAD peptide research" in online searches usually refers to one of two distinct research areas that get conflated. The first is NAD+ precursor research: clinical trials testing whether oral NMN, oral NR, or injectable NAD+ can raise NAD+ levels and produce health benefits in humans. This is an active field with over 30 published human trials and the 2026 PRISMA systematic review covering 113 total studies. The second is mitochondrial-derived peptide research: studies on MOTS-c, Humanin, and related peptides encoded by mitochondrial DNA. These are actual peptides that interact with energy metabolism and aging pathways. Both research areas are legitimate and scientifically interesting. They are separate fields studying separate molecules, even though the commercial market has merged them under one "NAD peptide" umbrella.

One specific search query worth addressing is "NAD peptide research MOTS-c." MOTS-c was identified in 2015 by a team at the University of Southern California as the first exercise-induced mitochondrial peptide. A 2021 study in Nature Communications (Reynolds et al.) showed that circulating MOTS-c levels rise acutely with exercise in humans and that MOTS-c injections improved exercise capacity and metabolic homeostasis in aged mice. As of September 2026, no completed human trial has tested therapeutic MOTS-c administration for clinical outcomes, though an FDA advisory committee voted 7-5 in July 2026 to recommend it for the Section 503A compounding list. That recommendation, if finalized, would allow compounding pharmacies to legally prepare MOTS-c for prescribed use, though it would not constitute FDA drug approval.

How to Raise NAD+ Levels (Without the "Peptide" Label or Price Tag)

If you landed on this page searching for "NAD peptide" because you want to raise your NAD+ levels, the most evidence-supported and cost-effective approach is oral supplementation with an NAD+ precursor. The two most studied options:

NMN (nicotinamide mononucleotide) is one enzymatic step away from NAD+ in the biosynthesis pathway. Twelve published randomized controlled trials have tested it in humans. Doses of 250 to 1,000 mg/day reliably raise blood NAD+ levels. NMN is sold as a dietary supplement.

NR (nicotinamide riboside) is converted to NMN by NR kinases, then to NAD+. Over 20 human RCTs have been published. NR performs comparably to NMN in blood NAD+ elevation at 14 days (Christen et al., 2026).

The cost difference is dramatic. A month of oral NMN supplementation at 500 mg/day runs approximately $30 to $60 depending on the brand. A single NAD+ IV session at a clinic costs $400 to $1,500. Over a year, that is $360 to $720 for oral supplementation versus $4,800 to $18,000 for monthly IV sessions. The clinical evidence for both delivery routes shows NAD+ elevation, but only oral precursors have a meaningful body of RCT data behind them.

If you decide to start with an oral precursor, the key quality markers to look for are third-party purity testing (certificate of analysis showing 99%+ purity by HPLC), a single active ingredient per capsule (no proprietary blends), and storage conditions that protect against heat and moisture degradation. NMN in particular is sensitive to temperature: reputable brands ship with cold packs and specify storage below 25°C. A published COA from an independent lab is the minimum baseline. If a brand does not make its COA accessible, that tells you something about its transparency standards.

For people who have tried oral precursors and want to explore injectable NAD+, the evidence-backed approach is to work with a physician who orders baseline labs (including blood NAD+ metabolite panels where available), prescribes through a USP 797-compliant compounding pharmacy, and monitors follow-up labs to confirm the intervention is producing measurable changes. Skipping the lab work and ordering compounded NAD+ vials from the cheapest online source is how adverse events happen in this space.

Common Misconceptions About "NAD Peptide"

These come up in the same order almost every time.

"NAD+ is a peptide because it gets injected." So are saline, vitamin C, and contrast dye for an MRI. The delivery method tells you nothing about molecular structure. (Insulin is injectable and happens to be a peptide, but that is the exception that proves the rule.)

"NAD+ is a peptide because my clinic calls it one." Some clinics use "peptide therapy" as a catch-all for their injectable services. It simplifies their marketing but sacrifices chemical accuracy. If your clinic calls NAD+ a peptide, that does not change the molecule's structure. It does tell you something about how carefully the clinic communicates.

"NAD+ must be a peptide because it works on the same pathways." Vitamin C and collagen both participate in skin maintenance. That does not make vitamin C a protein. Same logic applies here.

"I read that NAD+ is a peptide on a peptide research site." Several online peptide encyclopedias and vendor sites list NAD+ in their catalogs. They typically include a disclaimer noting that NAD+ is a coenzyme, not a peptide, but the listing itself reinforces the association. Read the fine print on those pages. Almost every reputable one acknowledges the distinction upfront.

"NAD+ and NMN are peptides used for anti-aging." NMN (nicotinamide mononucleotide) is a nucleotide. NAD+ is a dinucleotide. Neither contains amino acids or peptide bonds. Both are studied for anti-aging effects. Being studied for anti-aging does not make something a peptide. The anti-aging research space includes molecules from dozens of chemical classes: rapamycin (a macrolide), metformin (a biguanide), resveratrol (a polyphenol), senolytics (various classes). The chemistry defines the category, not the research application.

NAD+ Peptide Buffered Formulation: What Is It?

If you have seen "NAD+ buffered peptide" listed on a compounding pharmacy order, that refers to a pH-stabilized formulation of NAD+ for injection. The word "buffered" means the solution has been adjusted to a physiological pH (around 7.0 to 7.4) to reduce the stinging and tissue irritation that can occur with unbuffered NAD+ injections. Some formulations also add a small amount of bacteriostatic water for preservation.

The "peptide" in the name, again, is a commercial label. The vial contains NAD+, buffer salts, and sterile water. No actual peptide molecules are present unless the order specifically includes a peptide like BPC-157 or MOTS-c alongside the NAD+.

The term "NAD 500 peptide" or "NAD 500mg peptide" that appears in searches refers to a 500 mg vial of NAD+ for injection. The 500 mg describes the dose of NAD+ in the vial, not a peptide. These are sold through compounding pharmacies and require a physician's prescription. Quality varies between pharmacies, and there is no FDA standardization for compounded NAD+ preparations.

Frequently Asked Questions

Is NAD+ a peptide?

No. NAD+ is a dinucleotide coenzyme made of two nucleotides joined by phosphate groups. It contains zero amino acids and zero peptide bonds. Peptides are short chains of amino acids. They are entirely different molecular categories.

Why is NAD+ called a peptide?

Marketing. Longevity clinics and compounding pharmacies sell injectable NAD+ alongside actual peptides like BPC-157 and MOTS-c. The shared delivery method (injection) and shared sales channel created the association. The molecule did not change; the label did.

What is a NAD peptide injection?

A subcutaneous or intravenous injection of pharmaceutical-grade NAD+ dissolved in sterile saline. Despite the name, the product contains no peptides. It is pure NAD+. These injections are prepared by compounding pharmacies under physician prescription and are not FDA-approved drugs.

Is NAD+ the same as MOTS-c?

No. MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA. NAD+ is a coenzyme. They participate in overlapping metabolic pathways (both are involved in mitochondrial function and energy metabolism), but they are structurally and functionally distinct molecules.

What does NAD peptide do for the body?

NAD+ (not actually a peptide) carries electrons for energy production, activates sirtuins for gene regulation, fuels PARPs for DNA repair, and participates in over 500 enzymatic reactions. See What Is NAD+? for the full explanation.

What is the NAD peptide dosage?

For oral NMN: 250 to 1,000 mg/day based on clinical trials. For oral NR: 300 to 1,000 mg/day. For IV NAD+: 250 to 1,000 mg per session (no standardized protocol from RCTs). For subcutaneous NAD+: 100 to 500 mg (no RCT-based guideline).

Are NAD peptide injections safe?

Oral precursors (NMN, NR) have been well-tolerated across 33 human trials with no serious adverse events. IV and injectable NAD+ commonly cause transient side effects (chest tightness, nausea, injection-site stinging) that resolve quickly. No long-term safety data exists for injectable NAD+ in controlled trials.

Is it better to take NAD+ orally or by injection?

Oral precursors have far more clinical evidence, cost dramatically less, and reliably raise blood NAD+ levels. Injectable NAD+ bypasses digestion but has no published RCT demonstrating superior clinical outcomes. Most researchers and the 2026 PRISMA review conclude that oral precursors are the evidence-supported starting point.

Related Reading

• NAD+ Patches: Do They Work?
• NAD+ Nasal Spray: Does It Work?
• What Is NAD+? Benefits, Function & Why It Declines With Age
• NAD+ Injections: Benefits, Side Effects & Cost
• NAD+ IV Therapy: How It Works, Costs & Evidence
• NAD+ Supplements: Types, Evidence & How to Choose
• Best NAD+ Supplements in 2026
• What Is NMN? Benefits, NAD+ & Aging Research

Authoritative Resources

• Cleveland Clinic: NAD (Nicotinamide Adenine Dinucleotide)
• Ageing Research Reviews: NAD+ Supplementation PRISMA Systematic Review (2026)
• FDA: July 2026 Pharmacy Compounding Advisory Committee Meeting (MOTS-c, BPC-157)

References

1. Amjad S, Nisar S, Bhat AA, et al. Role of NAD+ in regulating cellular and metabolic signaling pathways. Molecular Metabolism. 2021;49:101195. doi:10.1016/j.molmet.2021.101195 View source (PubMed)
2. Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism. 2016;23(6):1127–1139. doi:10.1016/j.cmet.2016.05.006 View source (PubMed)
3. Gallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews. 2026;116:103057. doi:10.1016/j.arr.2026.103057 View source (PubMed)
4. Christen S, Redeuil K, Goulet L, et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nature Metabolism. 2026;8:62–73. doi:10.1038/s42255-025-01421-8 View source (PubMed)
5. Berven H, Svensen M, Eikeland H, et al. The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation. iScience. 2026;29(3):114764. doi:10.1016/j.isci.2026.114764 View source (PubMed)
6. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12:470. doi:10.1038/s41467-020-20790-0 View source (PubMed)

Written by Tao Wu. Last reviewed September 2026. This article is for informational purposes and does not constitute medical advice. Talk to your doctor before starting any new supplement.